8.3 C

A multi-hundred million pharmaceutical investment is expected in Lendava



The Prime Minister and the Minister of Economy will make a statement with representatives of Sandoz and Lek at 1:45 p.m

Prime Minister Robert Golob and Minister of Economy Matjaž Han met with the presidents of Sandoz and Lek and the president of Sandoz Slovenia. They are supposed to sign a letter of intent for a multi-hundred million investment in Lendava.

According to unofficial information from the N1 portal, the pharmaceutical group Sandoz, which includes Lek, will sign a letter of intent with the government for a multi-hundred million investment in Lendava. It is said to be Sandoz’s largest investment in Slovenia to date. It should bring around 200 new jobs. The investment could be supported by the state.

In the new production facility, which, according to the portal, should be built in two years, similar biological medicines would be produced. Lek already has a plant in Lendava where the production of anti-infectives and the packaging of final pharmaceutical forms takes place, employing 710 people.

Statement for the media at the Prime Minister’s meeting Robert Golob and the Minister of Economy Matjaž Han with the CEO of Sandoz Richard Saynor and to the president of the management of Lek and the president of Sandoz Slovenia Robert Ljolje is scheduled at 1:45 p.m.

Novartis also announced the establishment of a biotechnology park in Mengeš

Meanwhile, the Swiss pharmaceutical giant Novartis, the owner of Sandoz, also announced in January that it intends to establish the Life Science Park Mengeš biotechnology park in Mengeš with the Chinese company Porton, which supplies it with active pharmaceutical ingredients. Novartis will lease part of the vacant premises to Porton, and 300 new jobs will be created.

Novartis plans to spin off Sandoz as its generic division, and as part of this, it is expected to transfer Lek’s production of solid products in Ljubljana and the production of active ingredients and biological drugs in Mengš to the Slovenian company Novartis. The completion of the process is expected in the second half of the year.

Source: Rtvslo

Subscribe to our magazine


━ more like this


Please enter your comment!
Please enter your name here